个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：
Gu Chengyuan[1,2] ; Wang Zengjun[3] ; Lin Tianxin[4] ; Liu Zhiyu[5] ; Han Weiqing[6] ; Zhang Xuhui[7] ; Liang Chao[3] ; Liu Hao[4] ; Yu Yang[5] ; Xu Zhenzhou[6] ; Liu Shuang[7] ; Wang Jingen[8] ; Jia Linghua[8] ; Yao Xin[9] ; Liao Wenfeng[9] ; Fu Cheng[10] ; Tan Zhaohui[11] ; He Guohua[12] ; Zhu Guoxi[13] ; Fan Rui[14] ; Yang Wenzeng[15] ; Chen Xin[16] ; Liu Zhizhong[17] ; Zhong Liqiang[18] ; Shi Benkang[19] ; Ding Degang[20] ; Chen Shubo[21] ; Wei Junli[21] ; Yao Xudong[22] ; Chen Ming[23] ; Lu Zhanpeng[24] ; Xie Qun[25] ; Hu Zhiquan[26] ; Wang Yinhuai[27] ; Guo Hongqian[28] ; Fan Tiwu[29] ; Liang Zhaozhao[30] ; Chen Peng[31] ; Wang Wei[32] ; Xu Tao[33] ; Li Chunsheng[34] ; Xing Jinchun[35] ; Liao Hong[36] ; He Dalin[37] ; Wu Zhibin[38] ; Yu Jiandi[39] ; Feng Zhongwen[40] ; Yang Mengxiang[41] ; Dou Qifeng[42] ; Zeng Quan[43] ; Li Yuanwei[44] ; Gou Xin[45] ; Zhou Guangchen[46] ; Wang Xiaofeng[47] ; Zhu Rujian[48] ; Zhang Zhonghua[49] ; Zhang Bo[50] ; Tan Wanlong[51] ; Qu Xueling[52] ; Sun Hongliang[52] ; Gan Tianyi[52] ; Ye Dingwei[1,2,*1,*2] ;
机构： [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. [3]Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. [4]Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China. [5]Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, China. [6]Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Center, Changsha, Hunan 410013, China. [7]Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030000, China. [8]Department of Urology, Jiangxi Provincial People's Hospital, School of Medicine, Nanchang University, Nanchang, Jiangxi 330006, China. [9]Department of Urology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. [10]Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110043, China. [11]Department of Urology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010010, China. [12]Department of Urinary Surgery, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, Jiangsu 225300, China. [13]Department of Urology, Linfen People's Hospital, Linfen, Shanxi 041000, China. [14]Department of Urology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450006, China. [15]Department of Urology, The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, China. [16]Department of Urology, Chifeng Municipal Hospital, Chifeng Clinical Medical College of Inner Mongolia Medical University, Chifeng, Inner Mongolia 024000, China. [17]Department of Urology, Baogang Hospital, Baotou, Inner Mongolia 014010, China. [18]Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, China. [19]Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong 250014, China. [20]Department of Urology, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China. [21]Department of Urology, Xingtai People's Hospital, Hebei Medical University, Xingtai, Hebei 054001, China. [22]Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China. [23]Department of Urology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, China. [24]Department of Urology, Jining No. 1 People's Hospital, Jining, Shandong 272011, China. [25]Department of Urology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 519000, China. [26]Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. [27]Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410000, China. [28]Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu 210008, China. [29]Department of Urology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046011, China. [30]Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China. [31]Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China. [32]Department of Urology Surgery, Liuzhou People's Hospital Affiliated to Guangxi University of Science and Technology, Liuzhou, Guangxi 545200, China. [33]Department of Urology, Peking University People's Hospital, Beijing 100044, China. [34]Department of Urology, Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia 024036, China. [35]Department of Urology Surgery, The Key Laboratory of Urinary Tract Tumors and Calculi, The First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen, Fujian 361003, China. [36]Department of Urology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital, Chengdu, Sichuan 610047, China. [37]Department of Urology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. [38]Department of Oncology, Affiliated Zhejiang Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310030, China. [39]Department of Urology, Zhejiang Hospital, Hangzhou, Zhejiang 310030, China. [40]Department of Urology, Grand Hospital of Jincheng, Jincheng, Shanxi 048006, China. [41]Department of Oncology, Liaocheng People's Hospital, Liaocheng, Shandong 252004, China. [42]Department of Urology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, China. [43]Department of Urology, The Affiliated Hospital of Jiujiang University, Jiujiang, Jiangxi 332000, China. [44]Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, China. [45]Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. [46]Department of Urology, Subei People's Hospital of Jiangsu Province (Clinical Medical College, Yangzhou University), Yangzhou, Jiangsu 225001, China. [47]Department of Urology, Peking University International Hospital, Beijing 102206, China. [48]Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201300, China. [49]Department of Urology, Xinyu People's Hospital, Xinyu, Jiangxi 338000, China. [50]Department of Urology, Tangdu Hospital, The Air Force Medical University, Xi'an, Shaanxi 710038, China. [51]Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510000, China. [52]Clinical Research Center of Luye Pharma Group Ltd, Beijing 264003, China
出处：
DOI： 10.1097/CM9.0000000000002638
ISSN：

关键词： Prostatic neoplasms LY01005 Gonadotropin-releasing hormone agonist Efficacy Safety

摘要：
LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels.On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9%, 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3%, 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs. 1.4% [2/145]).LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.ClinicalTrials.gov, NCT04563936.Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：
Luye Pharma Group Ltd.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：内科
JCR分区：
出版当年[2023]版：
Q1 MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. [*1]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [*2]Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong’an Road, Shanghai 200032, China
推荐引用方式(GB/T 7714)：
Gu Chengyuan,Wang Zengjun,Lin Tianxin,et al.Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial[J].CHINESE MEDICAL JOURNAL.2023,136(10):1207-1215.doi:10.1097/CM9.0000000000002638.
APA：
Gu Chengyuan,Wang Zengjun,Lin Tianxin,Liu Zhiyu,Han Weiqing...&Ye Dingwei.(2023).Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.CHINESE MEDICAL JOURNAL,136,(10)
MLA：
Gu Chengyuan,et al."Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial".CHINESE MEDICAL JOURNAL 136..10(2023):1207-1215

相关文献

[1]促性腺激素释放激素激动剂对辐射所致大鼠卵巢功能损伤的防护作用研究 [2]促性腺激素释放激素激动剂对辐射所致大鼠卵巢功能损伤的防护作用研究 [3]促性腺激素释放激素激动剂在子宫内膜异位症和子宫平滑肌瘤治疗中的应用专家意见 [4]促性腺激素释放激素激动剂在子宫内膜异位症和子宫平滑肌瘤治疗中的应用专家意见 [5]Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis [6]Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis [7]Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study [8]Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis [9]Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial [10]Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号